HEDTMP (N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri(methylene phosphonic acid)) was labeled with 153Sm. The formation condition, stability, rabbit bone imaging and mouse bio-distribution of 153Sm -HEDTMP were investig...HEDTMP (N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri(methylene phosphonic acid)) was labeled with 153Sm. The formation condition, stability, rabbit bone imaging and mouse bio-distribution of 153Sm -HEDTMP were investigated. The results showed that weak basic media and high ligand’s concentration were favorable to form 153Sm-HEDTMP, and neutral or weak basic media increase the stability of 153Sm-HEDTMP. And the higher the con- centration of HEDTMP was, the more stable the labeling complex was. Bio-distribution study indicated the uptake of 153Sm-HEDTMP in skeleton was high ((25.68±1.22)ID%/g bone at 3 h post injection and (16.56±1.01)ID%/g bone at 48 h post injection), while the non-target tissue uptake and retention were relatively low, so 153Sm-HEDTMP is a promising bone tumor therapeutic agent.展开更多
To calculate a safe and effective 153Sm-EDTMP therapy dose, a whole-body scintigraphy technique for prospective individual dosimetry was developed and the results were compared with 5h urine collection method in 20 pa...To calculate a safe and effective 153Sm-EDTMP therapy dose, a whole-body scintigraphy technique for prospective individual dosimetry was developed and the results were compared with 5h urine collection method in 20 patients with bone metastases. Anterior and posterior whole-body images were obtained 10 min and 5 h after intravenous injection of 740 MBq 153Sm-EDTMP and the bone uptake value was determined. There is a close correlation between the bone uptake value obtained from the whole-body scintigraphy and 5 h urine collection method (r=0.93). The radiation absorption dose to red marrow was limited to 1.4 Gy and the administered activity calculated from bone uptake value by whole-body scintigraphy was 1.40-2.27GBq (mean 1.90 GBq). If the activity was calculated according to the standard body weight of 37 MBq.kg-1, the administered activity would be 1.75-2.41 GBq (mean 2.18), the radiation absorption dose to red marrow would be 1.37-2.27 Gy (mean 1.63 Gy), but at these doses significant myelotoxicity would be anticipated, thus emphasizing the need for individual prospective dosimetry.展开更多
文摘HEDTMP (N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri(methylene phosphonic acid)) was labeled with 153Sm. The formation condition, stability, rabbit bone imaging and mouse bio-distribution of 153Sm -HEDTMP were investigated. The results showed that weak basic media and high ligand’s concentration were favorable to form 153Sm-HEDTMP, and neutral or weak basic media increase the stability of 153Sm-HEDTMP. And the higher the con- centration of HEDTMP was, the more stable the labeling complex was. Bio-distribution study indicated the uptake of 153Sm-HEDTMP in skeleton was high ((25.68±1.22)ID%/g bone at 3 h post injection and (16.56±1.01)ID%/g bone at 48 h post injection), while the non-target tissue uptake and retention were relatively low, so 153Sm-HEDTMP is a promising bone tumor therapeutic agent.
基金Supported by the National Natural Science Foundation of China (No.29971027)
文摘To calculate a safe and effective 153Sm-EDTMP therapy dose, a whole-body scintigraphy technique for prospective individual dosimetry was developed and the results were compared with 5h urine collection method in 20 patients with bone metastases. Anterior and posterior whole-body images were obtained 10 min and 5 h after intravenous injection of 740 MBq 153Sm-EDTMP and the bone uptake value was determined. There is a close correlation between the bone uptake value obtained from the whole-body scintigraphy and 5 h urine collection method (r=0.93). The radiation absorption dose to red marrow was limited to 1.4 Gy and the administered activity calculated from bone uptake value by whole-body scintigraphy was 1.40-2.27GBq (mean 1.90 GBq). If the activity was calculated according to the standard body weight of 37 MBq.kg-1, the administered activity would be 1.75-2.41 GBq (mean 2.18), the radiation absorption dose to red marrow would be 1.37-2.27 Gy (mean 1.63 Gy), but at these doses significant myelotoxicity would be anticipated, thus emphasizing the need for individual prospective dosimetry.
